Alkermes to present new research on psychiatry and addiction portfolios at upcoming scientific conferences

0

DUBLIN, October 29, 2021 / PRNewswire / – Alkermes plc (Nasdaq: ALKS) today announced its intention to present the research from its psychiatry and addiction portfolios at upcoming scientific conferences this fall. Meetings include:

  • Psy Congress (29 October-Nov. 1, San Antonio and virtual);
  • International Society for Affective Disorders (ISAD) Conference (November 3-4, virtual);
  • Neuroscience Education Institute (NEI) Congress (November 4-7, Colorado Springs, Colorado. and virtual).

“Alkermes has been at the forefront of drug development in the fields of psychiatry and addiction for many years, and we remain committed to helping people living with these serious chronic conditions,” said Craig hopkinson, MD, medical director and executive vice president of research and development at Alkermes. “We are proud to participate in important scientific exchanges with key opinion leaders and clinicians at these medical congresses and hope that this data will significantly contribute to the knowledge base and the approach of the clinical community. to care for these patient populations. “

Highlights of upcoming presentations include:

  • Results of an online cross-sectional survey of clinical sites examining the impact of the COVID-19 pandemic on clinical operations, the use of telepsychiatry, and the management of care for patients with schizophrenia treated with antipsychotic drugs long-acting injectables;
  • New results from an analysis of health insurance claims evaluating opioid dispensing patterns in people with schizophrenia or bipolar disorder compared to matched controls over time;
  • Results of a structured benefit-risk assessment evaluating a combination of olanzapine and samidorphan for the treatment of adults with schizophrenia and bipolar I disorder.

The full list of Alkermes presentations by meeting includes:

Psy Congress, 29 October-Nov. 1, 2021
In-person and virtual posters

  • Poster # 109: Opioid Prescribing Patterns in Patients with Schizophrenia: Real Data from IBM® MarketScan® Research databases
  • Poster # 110: Opioid Prescribing Patterns in Patients with Bipolar Disorder: Real Data from IBM® MarketScan® Research databases
  • Poster # 108: A Structured Benefit-Risk Assessment to Evaluate a Combination of Olanzapine and Samidorphan for the Treatment of Schizophrenia and Bipolar I Disorder
  • Poster 4: Weight gain and co-morbidities associated with second-generation oral antipsychotics: analysis of patients with bipolar I disorder or schizophrenia
  • Poster n ° 95: Clinical management of patients with schizophrenia treated with long-acting injectable antipsychotics since the start of the COVID-19 pandemic, including the role of telepsychiatry

Virtual posters only

  • Treatment Patterns and Health Care Resource Use in Alcoholic Patients Who Start Taking Extended-Release Naltrexone: Analysis of Veterans’ Data
  • Population pharmacokinetic-pharmacodynamic analysis to explore the concentration-response relationship in patients with schizophrenia treated with olanzapine alone or in combination with samidorphan

ISAD Conference, 3-4 November 2021

  • Poster # P-001: A combination of olanzapine and samidorphan in adults with schizophrenia and bipolar I disorder: overview of clinical data

NEI Congress, November 4-7, 2021

  • Poster # 24: Opioid Prescribing Patterns in Patients with Bipolar Disorder: Real Data from IBM® MarketScan® Research databases
  • Poster # 25: Opioid Prescribing Patterns in Patients with Schizophrenia: Real Data from IBM® MarketScan® Research databases
  • Poster # 26: A Structured Benefit-Risk Assessment to Evaluate a Combination of Olanzapine and Samidorphan for the Treatment of Schizophrenia and Bipolar I Disorder
  • Poster # 27: Population pharmacokinetic-pharmacodynamic analysis to explore the concentration-response relationship in patients with schizophrenia treated with olanzapine alone or in combination with samidorphan
  • Poster # 29: Weight gain and co-morbidities associated with second-generation oral antipsychotics: analysis of patients with bipolar I disorder or schizophrenia
  • Poster n ° 28: Clinical management of patients with schizophrenia treated with long-acting injectable antipsychotics since the start of the COVID-19 pandemic, including the role of telepsychiatry

About Alkermès
Alkermes plc is a fully integrated global biopharmaceutical company developing innovative drugs in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on substance abuse, schizophrenia and bipolar I disorder, as well as a pipeline of product candidates in development for neurodegenerative disorders and cancer. Based at Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing site in Athlone, Ireland; and a manufacturing plant in Wilmington, Ohio. For more information, please visit the Alkermes website at www.alkermes.com.

Contacts in Alkermès:


For investors:

Alex Braun,

+1 781 296 8493

For the media:

Marisa Borgasano,

+1 781 609 6659

SOURCE Alkermes plc

Related links

https://www.alkermes.com


Source link

Share.

About Author

Leave A Reply